May 24, 2016/Cancer

Surgery Alone Found Insufficient To Treat Postop, Node-Positive, Stage III Rectal Cancer

Takeaway: Treatment should be localized

16-DDI-444-Stocchi-CQD-650×450

It’s a clinical conundrum without a clear answer: What’s the best approach for patients who undergo total mesorectal excision of Stage II-III rectal cancer based on negative node imaging, but who later turn out to harbor Stage III disease on pathology?

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Further treatment is recommended, as long as a patient can endure it, Cleveland Clinic researchers reveal in a follow-up study presented at Digestive Disease Week 2016.

One thing is clear: “Surgery alone in these cases is not optimal,” says Luca Stocchi, MD, Clinical Research Section Head, Colorectal Surgery. “The take-home message for other physicians is that even if node positive rectal cancer is only demonstrated by the assessment of the pathology specimen and was not visible at the time of the initial imaging, postoperative treatments, at least chemotherapy, should be given when the patient can tolerate that.”

In select patients, radiation might also be warranted.

Dr. Stocchi and his colleagues identified 218 pathologically node positive (cN-/pN+) patients from a prospectively collected database. Patients were initially staged with abdominopelvic CT, transrectal endoscopic ultrasound and/or pelvic MRI. Each patient underwent total mesorectal excision (TME) without preoperative chemoradiation.

Significantly different outcomes

The investigators classified patients into three groups to compare outcomes: 18 patients who received no postoperative treatment; 59 others who received either chemoradiotherapy or radiation alone; and 141 controls who had neoadjuvant chemoradiation plus surgery.

Advertisement

Dr. Stocchi acknowledges that some clinicians remain concerned about possible increased toxicity from postoperative chemoradiation, particularly after patients undergo a low colorectal anastomosis or a coloanal anastomosis. “Hypothetically, one might argue that incidental lymph node involvement found on the pathology specimen after the initial imaging studies were negative for lymph node involvement might be associated with a small burden of disease which could be treated with surgery alone.”

“The results of our study are in contrast with such a hypothesis.”

Compared with patients who received any adjuvant treatment and controls, patients who only had surgery experienced significantly poorer cancer outcomes during a follow-up of at least three years.

Oncologic Outcomes

5-year overall survival
No Postop Treatment
42.3%
Adjuvant Treatment
73.5%
Neoadjuvant Therapy + Surgery
66.4%
P value
0.004
5-year disease-free survival
No Postop Treatment
42.8%
Adjuvant Treatment
67.2%
Neoadjuvant Therapy + Surgery
57.3%
P value
0.005
5-year disease-specific survival
No Postop Treatment
54.7%
Adjuvant Treatment
85.7%
Neoadjuvant Therapy + Surgery
74.1%
P value
0.021
5-year local recurrence
No Postop Treatment
16.7%
Adjuvant Treatment
2.1%
Neoadjuvant Therapy + Surgery
9.3%
P value
0.211
5-year distant recurrence
No Postop Treatment
42.4%
Adjuvant Treatment
20.4%
Neoadjuvant Therapy + Surgery
37.2%
P value
0.016

“Surgery alone was insufficient in our study population because the impact of lymph node involvement remained significant, even though the involvement of the lymph nodes could not be demonstrated by the initial imaging studies,” Dr. Stocchi says.

Individualize treatment

“My recommendation would be that such patients should have postoperative chemotherapy,” Dr. Stocchi says. The study, however, was not powered to demonstrate if postoperative chemotherapy alone is sufficient. Therefore, the use of postoperative radiation therapy could also be considered in select cases if there is major concern about local recurrence, he says.

Advertisement

“Cleveland Clinic has a long, tradition of treating rectal cancer as well as surgical expertise in complex cases and high-risk patients,” Dr. Stocchi says. To ensure the best possible outcomes, routine evaluation of patients with rectal cancer is incorporated into Cleveland Clinic’s tumor board. This means surgical oncologists and patients can gain from the interdisciplinary collaboration among specialists from other clinical areas relevant to rectal cancer, including medical oncology, radiation oncology, pathology, radiology and genetic counseling.

Treatment should be individualized. Specific agents would be likely discussed during the tumor board with input from a medical oncologist, “but in good-risk patients, based on the data from node positive colon cancer, it would probably involve FOLFOX,” Dr. Stocchi says.

In addition, “there may be practical situations in which the patient’s age, comorbidity or the onset of postoperative complications prevent the optimal use of such adjuvant treatments,” he notes.

Related Articles

Women's health physician
April 16, 2024/Cancer
Watching Out for Primary Ovarian Insufficiency

An underdiagnosed condition in patients with cancer

Fluorescent imaging during small bowel surgery
April 11, 2024/Cancer/Surgical Oncology
Fluorescence Imaging Augments Surgical Inspection and Palpation for Small Bowel Carcinoid Tumors

Study demonstrates superior visualization of occult primary lesions

microwave ablation of liver tumor
150-Watt, Single-Antenna Microwave Ablation System Demonstrates Safety and Efficacy

New device offers greater tumor control for malignant liver lesions

viral-induced cancer
April 3, 2024/Cancer
Mechanism of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) May Serve as Clue to More Effective Treatment

Cleveland Clinic researchers discover what drives – and what may halt – virus-induced cancer

Dr. Mukherjee at Cleveland Clinic
April 1, 2024/Cancer/Blood Cancers
Many Patients with “Indolent” Systemic Mastocytosis Experience Rapid Decline and Lower Survival

First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention

Cleveland Clinic physiatrist
March 22, 2024/Cancer/Innovations
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Ad